Research in Social and Administrative Pharmacy
Volume 2, Issue 1 , Pages 22-37 , March 2006

Consumption and costs of antihypertensive drugs in Mexico: Are diuretic agents a standing technological trajectory?

  • M. Altagracia-Martínez, Ph.D.

      Affiliations

    • Departamento de Sistemas Biológicos, Universidad Autónoma Metropolitana–Xochimilco, Calzada del Hueso #160 Depto. 601-A, Col. ExHacienda de Coapa, 04850 México DF, México
    • Corresponding Author InformationCorresponding author. Tel.: +52 55 5483 7098/5603 0535; fax: +52 55 5603 0535.
    • ,
  • J. Kravzov-Jinich, Ph.D.

      Affiliations

    • Departamento de Sistemas Biológicos, Universidad Autónoma Metropolitana–Xochimilco, Calzada del Hueso #160 Depto. 601-A, Col. ExHacienda de Coapa, 04850 México DF, México
    • ,
  • M.D. Guadarrama-Atrizco, M.S.

      Affiliations

    • Departamento de Sistemas Biológicos, Universidad Autónoma Metropolitana–Xochimilco, Calzada del Hueso #160 Depto. 601-A, Col. ExHacienda de Coapa, 04850 México DF, México
    • ,
  • C. Rubio-Poo, Ph.D.

      Affiliations

    • FES-Zaragoza, Universidad Nacional Autónoma de México (UNAM), Mexico City, México
    • ,
  • A.I. Wertheimer, Ph.D.

      Affiliations

    • School of Pharmacy, Temple University, Philadelphia, PA, USA

Received 9 August 2005 ,Revised 21 October 2005 ,Accepted 26 October 2005.

References 

  1. Scrip Report. Hypertension: therapeutic advances and market opportunities (BS 888). PJB Publ. 1997;1–181
  2. The new “1999 World Health Organisation–International Society of Hypertension (WHO-ISH). Guidelines for the Management of Hypertension”. Guidelines set new definitions, update treatment for hypertension. Bull World Health Organ. 1999;77:293
  3. “Instituto Nacional de Estadística, Geografia e Informática” (INEGI) . Encuesta Nacional de Salud 2000 (ENSA 2000), Mexico DF, Mexico. Available from: <http://www.insp.mx/ensa/>Accessed September 2005
  4. Giugale MM, Lafourcade O, Nguyen VH. Mexico. A Comprehensive Development Agenda for the New Era. Washington, DC: The World Bank; 2001;409–446
  5. World Health Organization (WHO) . Selected health indicators: Mexico. Available from: <http://www3.who.int/whosis/country/indicators.cfm%3Fcountry=mex>Accessed June 2003
  6. Cutler JA, MacMahon SW, Furberg CD. Controlled clinical trials of drug treatment for hypertension: a review. Hypertension. 1989;13:136–144
  7. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA. 1997;277:739–745
  8. Chalmers J, Zanchetti A. The 1996 report of the World Health Organization expert committee on hypertension control. J Hypertens. 1996;14:929–933
  9. Collins R, Peto R, Godwin J, MacMahon S. Blood pressure and coronary heart disease. Lancet. 1990;336:370–371
  10. World Health Organization–International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration. Protocol for prospective collaborative overviews of major randomized trials of blood pressure lowering treatments. J Hypertens. 1998;16:1127–1137
  11. Altagracia M, Cimoli M, Kravzov J, Castillo R, Espejo O, Wertheimer A. Technical trajectories and QWERTY methodology: an application for pharmaceutical innovations. J Res Pharm Econ. 2000;10:51–81
  12. Utterback J, Abernathy W. A dynamic model of process and product innovation. OMEGA, Int J Manag Sci. 1975;3:630–656
  13. David PA. Clio and the economics of QWERTY. Am Econ Rev. 1985;75:332–337
  14. Dosi G. Opportunities, incentives and the collective patterns of technological change. Econ J. 1997;107:1530–1547
  15. Arthur WB. Competing technologies, increasing returns and lock-in by historical events. Econ J. 1989;99:116–131
  16. Arthur WB. Competing technologies: an overview. In:  Dosi G,  Nelson R,  Soete L editor. Technical Change and Economic Theory. London: Pinter; 1988;p. 591–607
  17. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial—the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582–1587
  18. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker Valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–1675
  19. Sharp DW. Angiotensin II blockade for heart failure: any hope left for original promise?. Sci Watch. 2002;13:1–5Available from: <http://www.sciencewatch.com>Accessed September 2003
  20. Wright JT The ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–2997
  21. US Department of Health and Human Services: The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Available from: <http://www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.pdf>Accessed June 2005
  22. Psaty B, Manolio T, Smith N, et al. Time trends in high blood pressure control and the use of antihypertensive medications in older adults. Arch Intern Med. 2002;162:2325–2332
  23. World Health Organization (WHO). Hypertension control. Report of a WHO Expert Committee. WHO, 1996, Technical Report Series No. 862.
  24. Staessen JA, Wang Ji-G, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001;358:1305–1315
  25. Wing L, Reid C, Ryan , The Second Australian National Blood Pressure Study Group , et al. A Comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583–592
  26. International Marketing Services (IMS Mexico): Mexican Pharmaceutical Market. Published by IMS AG Switzerland, 1999-2003.
  27. National Prescription Audit (Mexico). Published by IMS AG Switzerland, 1999-2003.
  28. WHO Collaborating Centre for Drug Statistics Methodology.ATC/DDD Database . Available from: <http://www.whocc.no/atcddd/>Accessed June 2005
  29. Economist Intelligence Unit: Mexico: Market Profile, 2004. The Economist. Available from: <www.eiu.com>. Accessed June 2005.
  30. Kravzov J, Altagracia M, Yamasaki M, Salgado H, Cardona C. Rx Price control methods in Mexico. In:  Wertheimer A,  Smith M editor. International Drug Regulatory Mechanisms. Binghamton, NY: Pharmaceutical Products Press; 2003;p. 151–180
  31. Comisión Nacional de Salarios Mínimos, México . Available from: <www.conasami.gob.mx>Accessed June 2005
  32. Instituto Nacional de Estadística, Geografía e Informática (INEGI). Encuesta Nacional de Ingresos y Gastos de los Hogares. INEGI, Mexico, 2002.

PII: S1551-7411(05)00141-5

doi: 10.1016/j.sapharm.2005.10.001

Research in Social and Administrative Pharmacy
Volume 2, Issue 1 , Pages 22-37 , March 2006

Article Tools

* Image Usage & Resolution